Nabriva Therapeutics (NASDAQ:NBRV) Stock Rating Reaffirmed by Needham & Company LLC

Share on StockTwits

Nabriva Therapeutics (NASDAQ:NBRV)‘s stock had its “buy” rating reissued by equities researchers at Needham & Company LLC in a research report issued to clients and investors on Wednesday, AnalystRatings.com reports.

Several other research analysts have also issued reports on NBRV. HC Wainwright set a $7.00 target price on Nabriva Therapeutics and gave the stock a “buy” rating in a research report on Sunday, August 18th. ValuEngine raised Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research report on Thursday, August 1st. BidaskClub raised Nabriva Therapeutics from a “sell” rating to a “hold” rating in a research report on Tuesday, November 5th. Zacks Investment Research lowered Nabriva Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, August 23rd. Finally, Wedbush reaffirmed an “outperform” rating and set a $5.00 target price on shares of Nabriva Therapeutics in a research report on Friday, August 9th. One equities research analyst has rated the stock with a sell rating, three have assigned a hold rating and five have given a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus price target of $6.79.

NASDAQ:NBRV traded down $0.09 during trading hours on Wednesday, reaching $1.90. 1,038,400 shares of the company were exchanged, compared to its average volume of 731,291. The company has a market capitalization of $1.46 billion, a P/E ratio of -1.17 and a beta of 2.42. The company has a debt-to-equity ratio of 0.87, a current ratio of 5.81 and a quick ratio of 5.67. Nabriva Therapeutics has a 1-year low of $1.12 and a 1-year high of $3.27. The business has a 50 day moving average of $1.93 and a 200 day moving average of $2.20.

Nabriva Therapeutics (NASDAQ:NBRV) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($0.24) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.28) by $0.04. The business had revenue of $6.92 million during the quarter, compared to analyst estimates of $1.23 million. Nabriva Therapeutics had a negative return on equity of 171.36% and a negative net margin of 910.45%. As a group, equities research analysts anticipate that Nabriva Therapeutics will post -1.12 earnings per share for the current fiscal year.

In other Nabriva Therapeutics news, CEO Theodore R. Schroeder purchased 50,000 shares of the firm’s stock in a transaction on Tuesday, August 27th. The stock was purchased at an average cost of $1.79 per share, for a total transaction of $89,500.00. Following the acquisition, the chief executive officer now owns 5,786 shares in the company, valued at approximately $10,356.94. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. Over the last quarter, insiders have acquired 64,977 shares of company stock valued at $119,951 and have sold 21,773 shares valued at $45,186. Company insiders own 3.32% of the company’s stock.

A number of institutional investors have recently modified their holdings of NBRV. FMR LLC grew its holdings in Nabriva Therapeutics by 77.0% during the 1st quarter. FMR LLC now owns 3,261,500 shares of the biotechnology company’s stock worth $7,958,000 after acquiring an additional 1,418,800 shares during the period. Renaissance Technologies LLC grew its holdings in Nabriva Therapeutics by 51.8% during the 2nd quarter. Renaissance Technologies LLC now owns 1,299,365 shares of the biotechnology company’s stock worth $3,157,000 after acquiring an additional 443,600 shares during the period. JPMorgan Chase & Co. grew its holdings in Nabriva Therapeutics by 92.7% during the 2nd quarter. JPMorgan Chase & Co. now owns 323,857 shares of the biotechnology company’s stock worth $719,000 after acquiring an additional 155,815 shares during the period. Morgan Stanley grew its holdings in Nabriva Therapeutics by 52.9% during the 2nd quarter. Morgan Stanley now owns 265,418 shares of the biotechnology company’s stock worth $645,000 after acquiring an additional 91,869 shares during the period. Finally, Wells Fargo & Company MN acquired a new stake in Nabriva Therapeutics during the 2nd quarter worth about $169,000. Hedge funds and other institutional investors own 3.90% of the company’s stock.

Nabriva Therapeutics Company Profile

Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection.

Recommended Story: If I purchase shares through a brokerage account, am I the holder of record?

Analyst Recommendations for Nabriva Therapeutics (NASDAQ:NBRV)

Receive News & Ratings for Nabriva Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nabriva Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.